Physician profile
Hamid Mahmood
NPI 1104914985
$1,129.95
in general payments reported to CMS, 2019-2025
16 companies · $303 in 2025
The $303 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $188 · 2021: $258 · 2022: $48.90 · 2023: $41.14 · 2024: $36.41 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $380.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $219.87 | 2019-2021 | |
| Pfizer INC. | $128.82 | 2020-2024 | |
| Amgen INC. | $128.71 | 2019-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $124.58 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $115.78 | 2025 | Austedo Xr |
| Lilly USA, LLC | $89.54 | 2020-2025 | Jardiance |
| Baxter Healthcare | $68.82 | 2025 | Hillrom - Monarch Airway Clearance System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.91 | 2019-2021 | |
| Biogen, INC. | $42.88 | 2025 | Skyclarys |
| Astrazeneca Pharmaceuticals LP | $36.43 | 2021-2025 | Farxiga |
| Kerecis Limited | $30.26 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.50 | 2025 | Caplyta |
| Eisai INC. | $21.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.82 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.15 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $10.88 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamid Mahmood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.